Diagnostic fetal testing for pregnancies suspected to be affected with Smith-Lemli-Opitz syndrome (SLOS).
Polymerase Chain Reaction/Sequencing
Fetal Specimen: Two T-25 flasks at 80 percent confluent culture of amniocytes. If the client is unable to culture amniocytes, this can be arranged by contacting ARUP Client Services at (800) 522-2787.
Maternal Specimen: Lavender (K2EDTA), Lavender (K3EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Cultured Amniocytes: Fill flask with culture media. Transport two T-25 flasks at 80 percent confluent of culture amniocytes filled with culture media.
Maternal Specimen: Transport 3 mL whole blood (Min: 1mL)
Fetal Specimen: CRITICAL ROOM TEMPERATURE. Must be received within 48 hours of shipment due to liability of cells.
Maternal Specimen: Room temperature.
Maternal sample is recommended for proper test interpretation. Order Maternal Cell Contamination, Maternal Specimen. This can be arranged by contacting ARUP genetic counselors at (800) 242-2787 ext. 2141. Pateient History Form is available on the ARUP Web site or by contacting ARUP Client Services.
Fetal Specimen: Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
Maternal Specimen: Ambient: 72 hours; Refrigerated: 1week; Frozen: Unacceptable
Background information for Smith-Lemli-Opitz Syndrome (DHCR7) Sequencing, Fetal:
Characteristics: Smith-Lemli-Opitz syndrome (SLOS) is caused by mutations in the DHCR7 gene that disrupt the final step of cholesterol biosynthesis. Affected individuals typically have elevated serum concentration of 7-dehydrocholesterol (7-DHC). Characteristic findings include growth deficiency, postaxial polydactyly, 2-3 toe
syndactyly, intellectual disability, cardiac defects, feeding difficulty, congenital cataracts, sensorineural hearing loss, and characteristic facial features. Males with SLOS may have genitourinary anomalies such as hypospadias, cryptorchidism or undermasculinization of the external genitalia.
Incidence: 1 in 10,000- 1 in 60,000 live births.
Inheritance: Autosomal recessive.
Cause: Pathogenic germline mutations in the DHCR7 gene.
Clinical Sensitivity: 96 percent.
Methodology: Bidirectional sequencing of the entire DHCR7 coding region and intron/exon boundaries.
Analytical Sensitivity and Specificity: Greater than 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations, mutations in non-coding exons 1-2, and large deletion/duplications will not be detected. Mutations in genes other than DHCR7 are not evaluated.
For quality assurance purposes, ARUP Laboratories will confirm the above result at no charge following delivery. Order Confirmation of Fetal Testing and include a copy of the original fetal report (or the mother's name and date of birth) with the test submission. Please contact an ARUP genetic counselor at (800) 242-2787 extension 2141
prior to specimen submission.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
81405; 81265 Fetal Cell Contamination (FCC)
|Component Test Code*||Component Chart Name||LOINC|
|0050548||Maternal Contamination Study Fetal Spec||59266-7|
|0050612||Maternal Contam Study, Maternal Spec||31208-2|
|2011705||SLOS (DHCR7) Seq FE - Specimen||31208-2|
|2011706||SLOS (DHCR7) Seq FE - Interpretation||55195-2|